Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
80

Summary

Conditions
Advanced Solid Tumors
Type
Interventional
Phase
Phase 2
Design
Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

The study population is about 200 patients with advanced solid tumors, who fails or cannot tolerate standard therapies, or for whom no effective standard therapy is available, or who refuses standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated and Toripalimab 240mg wil...

The study population is about 200 patients with advanced solid tumors, who fails or cannot tolerate standard therapies, or for whom no effective standard therapy is available, or who refuses standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated and Toripalimab 240mg will be intravenously administered every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. For Toripalimab, the upper time limit for treatment is 2 years. The primary objective is safety of safety run-in (about 6 patients) and objective response rate (ORR) of Surufatinib combined with Toripalimab in patients with advanced solid tumors.

Tracking Information

NCT #
NCT04169672
Collaborators
Not Provided
Investigators
Principal Investigator: Lin Shen Beijing Cancer Hospital